Leap Therapeutics to Present at the 2017 Ladenburg Thalmann Healthcare Conference
September 19 2017 - 6:00AM
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today
announced that Christopher K. Mirabelli, Ph.D., Chairman,
President, and Chief Executive Officer, will present a corporate
overview at the 2017 Ladenburg Thalmann Healthcare Conference being
held at the Sofitel Hotel in New York City on September 26, 2017.
2017 Ladenburg Thalmann Healthcare Conference –
Leap Presentation Details:Date: September 26, 2017 Time: 11:30 A.M.
Eastern Time
The presentation will be webcast live and may be
accessed on the Investors page of the company’s website at
www.investors.leaptx.com, where a replay of the event will also be
available for a limited time.
About Leap TherapeuticsLeap
Therapeutics’ (NASDAQ:LPTX) most advanced clinical candidate,
DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1
(DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical
trials in patients with esophagogastric cancer and biliary tract
cancer, with an emerging focus on patients with defined mutations
of the Wnt pathway and in combination with immune checkpoint
inhibitors. Leap’s second clinical candidate, TRX518, is a novel,
humanized GITR agonist monoclonal antibody designed to enhance the
immune system’s anti-tumor response that is in two monotherapy
studies. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are
available via EDGAR at http://www.sec.gov or via
http://www.investors.leaptx.com/.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. These statements include statements
relating to Leap’s expectations with respect to the development and
advancement of DKN-01, TRX518, and other programs, including the
initiation, timing and design of future studies, enrollment in
future studies, business development, and other future
expectations, plans and prospects. Leap has attempted to identify
forward looking statements by such terminology as ‘‘believes,’’
‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’
‘‘projects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’
‘‘should,’’ or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Although
Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not
limited to: the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; the
ability to complete a financing or form business development
relationships to fund our expenses; the outcome, cost, and timing
of our product development activities and clinical trials; the
uncertain clinical development process, including the risk that
clinical trials may not have an effective design or generate
positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our plans to research,
develop, and commercialize our drug product candidates; our ability
to achieve market acceptance of our drug product candidates;
unanticipated costs or delays in research, development, and
commercialization efforts; the applicability of clinical study
results to actual outcomes; the size and growth potential of the
markets for our drug product candidates; our ability to continue
obtaining and maintaining intellectual property protection for our
drug product candidates; and other risks. Detailed information
regarding factors that may cause actual results to differ
materially will be included in Leap Therapeutics’ periodic filings
with the Securities and Exchange Commission (the "SEC"), including
Leap Therapeutics’ Form 10-K that Leap filed with the SEC on March
31, 2017. These statements are only predictions and involve known
and unknown risks, uncertainties, and other factors. Any forward
looking statements contained in this release speak only as of its
date. We undertake no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:
Douglas E. OnsiChief Financial OfficerLeap Therapeutics,
Inc.donsi@leaptx.com617-714-0360
Argot Partners
Susan Kim212-203-4433susan@argotpartners.com
or
Heather Savelle617-663-4863heather@argotpartners.com
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From May 2024 to Jun 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jun 2023 to Jun 2024